BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd ADR ONC
News
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma
BeOne Medicines to Present at the Jefferies Global Healthcare Conference
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Medicines Says Esophageal Cancer Treatments Had Higher Survival Rates in Phase 3 Study
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne Medicines Up Nearly 6%, on Pace for Largest Percent Increase Since November 2025 — Data Talk
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
BeOne Medicines Gets FDA Accelerated Approval for Lymphoma Drug
BeOne Medicines Shares Surge After Robust First-Quarter
BeOne Medicines Lymphoma Drug Gets FDA Priority Review
Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment
BeOne Medicines Gets Breakthrough Therapy Designation for Sonrotoclax
United States